Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-07-08

Clinical Trial Update: Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast [NA]

View source ↗

Summary

The clinical trial evaluating lapatinib for ductal carcinoma in situ (DCIS) of the breast has been terminated, with results posted on 2015-07-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tykerb (lapatinib)

Snippet

Sponsor: Indiana University | Conditions: Ductal Carcinoma in Situ | NA | Status: TERMINATED | Results posted: 2015-07-08